BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32265996)

  • 1. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
    Ewertowska M; Grześk E; Urbańczyk A; Dąbrowska A; Bąbol-Pokora K; Łęcka M; Kołtan S
    Allergy Asthma Clin Immunol; 2020; 16():22. PubMed ID: 32265996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
    Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
    Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
    Bloomfield M; Klocperk A; Zachova R; Milota T; Kanderova V; Sediva A
    Front Pediatr; 2021; 9():697706. PubMed ID: 34350147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
    Yang X; Xi R; Bai J; Pan Y
    Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.
    Yin Z; Tian X; Zou R; He X; Chen K; Zhu C
    Front Immunol; 2021; 12():813261. PubMed ID: 34992612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients.
    Tessarin G; Rossi S; Baronio M; Gazzurelli L; Colpani M; Benvenuto A; Zunica F; Cardinale F; Martire B; Brescia L; Costagliola G; Luti L; Casazza G; Menconi MC; Saettini F; Palumbo L; Girelli MF; Badolato R; Lanzi G; Chiarini M; Moratto D; Meini A; Giliani S; Bondioni MP; Plebani A; Lougaris V
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33080915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
    Redenbaugh V; Coulter T
    Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
    Carpier JM; Lucas CL
    Front Immunol; 2017; 8():2005. PubMed ID: 29387064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.
    Rivalta B; Amodio D; Milito C; Chiriaco M; Di Cesare S; Giancotta C; Conti F; Santilli V; Pacillo L; Cifaldi C; Desimio MG; Doria M; Quinti I; De Vito R; Di Matteo G; Finocchi A; Palma P; Trizzino A; Tommasini A; Cancrini C
    Front Pediatr; 2021; 9():703853. PubMed ID: 34540765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated review on activated PI3 kinase delta syndrome (APDS).
    Singh A; Joshi V; Jindal AK; Mathew B; Rawat A
    Genes Dis; 2020 Mar; 7(1):67-74. PubMed ID: 32181277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
    Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
    Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of mortality and survival rates for APDS.
    Hanson J; Bonnen PE
    Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
    Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
    J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
    Zhao P; Huang J; Fu H; Xu J; Li T; Zhang X; Meng Q; Zhang L; Tan L; Zhang W; Chen H; Lu X; Ding Y; He X
    Pediatr Rheumatol Online J; 2024 Jan; 22(1):24. PubMed ID: 38287413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.
    Thouenon R; Moreno-Corona N; Poggi L; Durandy A; Kracker S
    Front Pediatr; 2021; 9():652405. PubMed ID: 34249806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
    Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.